Table 3. ERK and Src inhibitors do not sensitize tumor cells to CTS-induced cell death.

Treatment	MCF7	MDAMB231
Control	100 ± 3.04	100 ± 17.7
500 nM Ouabain	89.56 ± 3.58	85.06 ± 12.69
5 µM ERK Inhibitor	104.10 ± 0.26	103.66 ± 10.42
10 µM Src Inhibitor	97.08 ± 2.26	86.60 ± 12.94
Ouabain + ERK Inhibitor	83.69 ± 1.72	77.60 ± 9.51
Ouabain + Src Inhibitor	81.14 ± 2.26	76.82 ± 12.15

Viability is displayed as the percentage of viable cells relative to untreated control; mean ± SE; n=3. Differences in viability from treatments with ouabain only compared to with ouabain plus inhibitor were not statistically significant (p>0.05).